Kanilad (Lacosamide)

Lacosamide is used in the management of epilepsy, specifically targeting focal seizure activity.

• Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens.
• Focal seizures: provides additional seizure control as an adjunctive agent.
• Adjunctive therapy in epilepsy: enhances overall seizure management when combined with other approved medications.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyperexcitable neuronal membranes and diminishing repetitive neuronal firing. By selectively targeting the slow inactivation phase, it reduces the propagation of epileptiform activity without significantly affecting normal neuronal conduction.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: transient sensation of light‑headedness or imbalance.
• Nausea: mild to moderate stomach upset.
• Fatigue: increased tiredness or lack of energy.
• Headache: mild to moderate pain in the head region.
• Blurred vision: temporary visual disturbances.
• Diplopia: occasional double vision.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm requiring medical attention.
• Suicidal ideation: emergence of thoughts of self‑harm.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: elevated liver enzymes or liver injury.
• Respiratory depression: slowed breathing, especially with CNS depressants.
• Anaphylactic reaction: rare but potentially life‑threatening allergic response.

When prescribing lacosamide, clinicians should consider several safety measures to minimize risk.

• Monitor cardiac function: obtain baseline ECG and watch for PR‑interval changes.
• Assess renal function: adjust dosing in patients with significant impairment.
• Avoid abrupt discontinuation: taper gradually to prevent seizure worsening.
• Use caution in hepatic impairment: monitor liver enzymes regularly.
• Pregnancy: risk category unknown; discuss potential benefits and risks with the patient.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels.
• CYP3A4 inducers (e.g., rifampin): may reduce lacosamide exposure.
• Other sodium channel blockers (e.g., carbamazepine): heightened risk of CNS depression.

Moderate Interactions (Monitor Closely)

• Carbamazepine: may lower lacosamide concentrations, requiring dose adjustment.
• Anticoagulants (e.g., warfarin): monitor INR for potential changes.
• Alcohol: can enhance central nervous system effects, increasing dizziness or sedation.